Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,472 total articles
Amazon's increased equity position in Anthropic changes the calculus for investors. This trade nails down a mid-term long on AMZN that leans on reduced perceived financing risk, improved AWS AI optionality, and a near-term re-rating catalyst set around product/service rollouts and earnings. Entry $170.00, target $210.00, stop $150.00.
Oracle’s update after Q4 2026 leaves the company with accelerating cloud revenue, a healthy backlog and a still-reasonable P/E for a scaled enterprise software vendor. Yes, free cash flow is negative and leverage is high, but the business dynamics — strong ROE, predictable recurring revenue and hyperscaler AI spend — make a disciplined long positio…
StealthGas (GASS) is a small-cap LPG shipowner trading at roughly 0.5x book and a single-digit PE after a string of asset sales and improved liquidity. Management says the balance sheet is unlevered and the company has raised cash through vessel disposals while locking in period charters. The setup favors a mid-horizon swing trade: entry $9.15, sto…
ServiceNow is trading below its 52-week midrange after a pullback; fundamentals show durable growth, $29B backlog, and $4.58B free cash flow. Valuation is premium, but multiple compression already priced in much of the near-term risk. We present an actionable mid-term long with an entry at $125.00, a $150.00 target and a $115.00 stop loss (45 tradi…
Gold.com (GOLD) is a small-cap precious-metals dealer with meaningful free cash flow, a modest P/E and a debt footprint that’s manageable for the business model. The shares recently pulled back into the $45 area after a run; technicals and fundamental cash generation argue for a mid-term long with a clear stop. This trade idea lays out entry, stop …
Box is growing revenue in double digits on a constant-currency basis while generating solid free cash flow. At a ~$4.6B market cap and trading near $33, the risk-reward favors a long position if you size it and use a tight stop. This trade targets $41 over a 180 trading-day horizon with a $30.50 stop.
Strategy Inc. (MSTR) has become a de facto Bitcoin proxy and its share price moves often amplify CEO Michael Saylor's treasury actions. With Saylor beginning to sell and the company signaling up to $1.25B in Bitcoin sales to fund buybacks and preferred payments, this trade idea flips the narrative: use near-term supply events as low-risk entries. W…
Rumble's acquisition of Northern Data and a multi-year Together AI contract transform the company from a niche video platform into an emerging independent GPU cloud provider. At $9.26 the market prices heavy execution and profitability risk into the equity. This trade idea buys that risk with a defined stop and a 180-trading-day horizon to let GPU …
Alibaba's Q2 print scared the market because of a one-time surge in AI infrastructure spending and a regulatory fine, but underlying Cloud revenue growth of 45% and a reasonable market cap/P-E profile create a compelling swing trade. Enter near $121, stop at $105, target $160 over the next 45 trading days.
Lucid (LCID) trades like a beaten growth name with intact technology and a thin float. At a market cap near $1.9B and an enterprise value above $4.7B, the stock is pricing in persistent execution failure. Recent activism and a high-profile stake have re-opened the path to a supply-and-deliver turnaround. This trade targets a mid-term recovery to $1…
FedEx is trading near multi-month highs after steady operational recovery and market dynamics that potentially favor third-party carriers. The company posts strong free cash flow, a reasonable valuation (EV/EBITDA ~9.2, P/E ~18), and a modest dividend. This trade idea proposes a long entry at $338.00 with a $370.00 target over the next 45 trading d…
Progressive's July updates show premium growth slowing while combined ratios remain attractive and investment float continues to support earnings. At roughly $222, the stock trades at ~11x earnings with a strong capital position and healthy free cash flow. We propose a mid-term long trade to capture a re-rating if growth quality steadies and invest…
Kinder Morgan is consolidating near $31-$32 after a strong run. With a $71.4B market cap, a 3.7% yield, low leverage and a sizable backlog plus a new 35.1% stake in a $5B pipeline JV, the setup favors a measured long. This trade targets a re-test of the 52-week high and continued re-rating as expansion projects begin to convert to contracted cash f…
Hut 8 has moved from crypto mining to long-duration AI infrastructure contracts, including a headline 15-year, $9.8 billion lease for 352 MW. The market cap of roughly $10.5 billion and enterprise value near $10.96 billion leaves room for upside if contracted revenue and capacity monetization continue. This trade idea lays out a long-term (180 trad…
Cerebras (CBRS) sells an unusual, high-performance advantage: wafer-scale silicon optimized for ultra-low-latency inference. The stock trades well below its 52-week high after a post-IPO reset, but fundamentals show rapid revenue growth and strategic partnerships that can drive adoption in latency-sensitive AI applications. This is a high-risk, hig…
JOYY has rallied into fresh 52-week highs as investor sentiment around BIGO and leadership recognition improves. The stock looks buyable on momentum and an attractive ~6.4% yield, but technicals, rising short interest, and questions about cash quality argue for a disciplined, mid-term trade with a clear stop.
Agora is trading at a sub-$400M market cap while producing mid-teens revenue growth, sustained GAAP profitability, and rapid adoption of conversational AI products. At $4.145, the risk/reward favors a tactical long for investors willing to accept execution and China exposure risks. Entry $4.145, target $6.50, stop $3.50.
SM Energy ($35.75) looks positioned to outpace peers over the next 45 trading days as hedging friction fades, free cash flow remains robust ($757.8M), and valuation multiples are compressed (EV/EBITDA 4.44; P/E ~7). I prefer a mid-term long with an entry at $35.75, a stop at $30.50 and a target of $44.00 — a trade that captures oil upside while res…
Olin's share price has been punished by an unplanned vinyl chloride monomer plant shutdown and legal noise around the Huntsman merger. The disruption is a one-time cash hit of about $40 million to Q2 adjusted EBITDA with an estimated $20 million follow-through in Q3. At $17.29, the stock is trading near its 52-week low, yields 4.6%, and still gener…
Alvopetro Energy (ALVOF) trades at $7.10 with neutral momentum and a history of elevated short activity. Management has positioned the name as high-margin with a covered dividend. Liquidity and opacity are real risks, but the technical setup, modest RSI, and one-day days-to-cover give a defined risk-reward for a 45-trading-day swing trade.
Meta owns one of the largest AI compute footprints on the planet. If management moves aggressively to rent spare GPU capacity through inference/finetune marketplaces and third-party cloud deals, revenue upside and margin expansion can follow quickly. This is a mid-term trade: enter at $450, stop $390, target $540 on a 45 trading day horizon, with a…
Bonterra Energy (BNEFF) is an overtly levered oil & gas-style play trading on the OTC market around $4. Technicals are neutral-to-bullish, short interest has collapsed from spring highs and short-volume spikes show continued active shorting on rallies. If commodity prices stay supportive, this structure can produce a rapid move higher. This is a hi…
Clover Health is an actionable long thanks to accelerating Medicare Advantage membership, demonstrable AI-driven care improvements, improving free cash flow and a valuation that prices growth modestly. This trade idea lays out a mid-term plan centered on enrollment catalysts and recurring care-management economics while flagging regulatory, data an…
Stantec's $9.0B backlog, double-digit EPS growth and 17%+ adjusted EBITDA margins create a runway for continued organic growth. The stock trades at ~22.8x earnings with EV/EBITDA ~11.7x and an enterprise value of ~$9.34B, leaving room for upside if management converts backlog into revenue and sustains margins. We recommend buying STN with a clear e…
TG Therapeutics has transitioned from small-cap promise to commercial-stage execution. BRIUMVI's accelerating sales, upgraded 2025 guidance and an active product expansion roadmap justify upgrading the rating to Buy. This trade idea lays out an entry at the current level, a protective stop and a mid-term target driven by continued uptake and upcomi…
